Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical
Healing is usually complete at about six weeks, but your results will continue to emerge over the course of the following months
Eur J Paediatr Neurol
The medication is injected intramuscularly-commonly into the upper arm, gluteal muscle, or thigh
